Guidance: Thierry Pieton: For the second quarter, we expect EPS in the range of $1.32 to $1.34, which includes a roughly neutral impact from foreign exchange at recent rates.
Demand and orders: Geoffrey Martha: Organic revenue growth was 13.7%, reflecting strong underlying market demand and excellent execution across our businesses.
Margins: Thierry Pieton: This resulted in an adjusted operating margin of 23.7%, up 10 basis points from the prior year, while we continue to invest behind our highest priority growth opportunities.
Analyst Q&A
Analyst Michael Kratky asked: So congrats on the strong quarter. Really encouraging to see the 35% sequential growth for your U.S. Affera installed base after 40% last quarter. So can you provide any additional color on utilization trends in centers after they've added an Affera system? Management Geoffrey Martha answered: Well, so first of all, 75% of our U.S. installed base are at high-volume centers, right? So right now, we're still concentrated in these high-volume centers, which is not a bad thing. But it also tells us we've got room to run in the lower volume centers across the U.S. 30% of our accounts are doing 70% of the ablations, right? These are high-volume centers. That's the 300-plus ablations a year. That's what we define as a high-volume center. And then many of these large accounts have only 1 or 2 systems, and they're asking for more.
